Fax: (732) 253-3953
DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer
Version of Record online: 14 JUL 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 4, pages 888–898, 15 February 2012
How to Cite
Taunk, N. K., Goyal, S., Wu, H., Moran, M. S., Chen, S. and Haffty, B. G. (2012), DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer. Cancer, 118: 888–898. doi: 10.1002/cncr.26352
- Issue online: 3 FEB 2012
- Version of Record online: 14 JUL 2011
- Manuscript Accepted: 9 MAY 2011
- Manuscript Revised: 25 APR 2011
- Manuscript Received: 1 MAR 2011
- DEAD box 1 (DDX1);
- radiation therapy;
- molecular markers;
- ipsilateral breast tumor recurrence (IBTR);
- early stage breast cancer
DEAD box 1 (DDX1) is an RNA helicase with a number of roles, including translation initiation, RNA splicing and modification, and possibly DNA double-strand break repair. Amplification of DDX1 expression has been implicated in tumors including neuroblastoma, Wilms tumor, retinoblastoma, and testicular carcinoma. The purpose of this study was to evaluate the prognostic significance of DDX1 expression in patients with breast cancer treated with breast-conserving therapy.
Paraffin-embedded specimens from 282 women with node-negative stage 1 and 2 breast cancer treated with breast-conserving surgery and radiation therapy were constructed into tissue microarrays and stained for DDX1. The molecular profiles were correlated with clinicopathologic factors and overall, local, and distant metastatic-free survival.
DDX1 positivity was identified in 142 (50%) patients. The median age at diagnosis was 53 years. Eighty percent of the patients had T1 disease; 11% were HER2neu-positive, and 18% had triple-negative disease. DDX1 negativity was strongly associated with triple-negative phenotype (P = .01). DDX1 positivity was found to be associated with improved local relapse-free survival (96% vs 85%, P = .0233), distant metastatic-free survival (95% vs 85%, P = .0320), and overall survival (92% vs 84%, P = .0474) at 10 years.
Node-negative, early stage breast cancer patients with high levels of DDX1 were found to have a significant improvement in local control, distant metastatic-free survival, and overall survival compared with patients with low levels of DDX1. Cancer 2012;. © 2011 American Cancer Society.